Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung Cancer.

BACKGROUND/AIM: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side-effect of taxane-based treatments. This study aimed to assess the efficacy and safety of a combined compression and cooling therapy for CIPN prevention in patients with lung cancer receiving taxane-containing regimens.

PATIENTS AND

METHODS

We retrospectively analyzed 53 patients with advanced lung cancer treated with taxane-based chemotherapy between April 2021 and March 2023. Patients underwent compression therapy using surgical gloves and elastic stockings, combined with cooling gloves and foot ice pillows, during chemotherapy infusion.

RESULTS

CIPN incidence was 20.8%, with no cases of grade ≥3 neuropathy. Paclitaxel and nab-paclitaxel showed lower CIPN rates (19.0% and 15.0%, respectively) compared to docetaxel (33.3%). No patients required chemotherapy dose reductions, and adverse events related to the therapy were mild and reversible.

CONCLUSION

Combined compression and cooling therapy appears to be a safe, feasible, and non-pharmacologic strategy for reducing CIPN in taxane-treated lung cancer patients. Further prospective validation is warranted.